From early 2021 through the middle of 2025, small-cap biotech stocks significantly underperformed the broader market.
The FDA has embraced accelerated approval pathways to help biotechnology companies bring forth promising therapies to patients at a faster pace.
Intra-Cellular Therapies, a commercial-stage biotech focused on treatments for psychiatric disorders, was acquired by Johnson & Johnson, for $14.6 billion.
A customized collection of grant news from foundations and the federal government from around the Web.

In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.